Literature DB >> 22231585

Development of molecular techniques for imaging and treatment of tumors.

U Haberkorn1, A Markert, M Eisenhut, W Mier, A Altmann.   

Abstract

With the advances in molecular biology and biochemistry new imaging and treatment modalities based on the biological properties of tissues have been developed. In oncology, the major progress has been achieved using peptide and antibody targeting vectors. Besides the identification of new target structures, progress in molecular biology also made new techniques for the development of new biomolecules. This relies on the identification of lead compounds and on the screening of various derivatives of these compounds one at a time. The principle of high-troughput methods for the identification of novel high affinity binders is to generate a vast library of possible variants of the molecule of interest and screen the population for the few variants that show the property of interest. The attracting feature of the concept arises from the huge number of candidate molecules that can be used for further evaluation. After the characterization of the structure-function relationships for the lead compounds found in this process further improvement by rational design of analogs can be performed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22231585

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  2 in total

1.  Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer.

Authors:  Xiao-Jian Han; Ling-Fei Sun; Yuki Nishiyama; Bin Feng; Hiroyuki Michiue; Masaharu Seno; Hideki Matsui; Kazuhito Tomizawa
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

2.  Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma.

Authors:  Xiao-Jian Han; Yong-Fang Wei; Yu-Ying Wan; Li-Ping Jiang; Jian-Feng Zhang; Hong-Bo Xin
Journal:  Int J Mol Med       Date:  2014-09-04       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.